224 related articles for article (PubMed ID: 28406934)
1. DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.
Artzi M; Even-Sapir E; Lerman Shacham H; Thaler A; Urterger AO; Bressman S; Marder K; Hendler T; Giladi N; Ben Bashat D; Mirelman A
PLoS One; 2017; 12(4):e0175424. PubMed ID: 28406934
[TBL] [Abstract][Full Text] [Related]
2. Prospective clinical and DaT-SPECT imaging in premotor
Sierra M; Martínez-Rodríguez I; Sánchez-Juan P; González-Aramburu I; Jiménez-Alonso M; Sánchez-Rodríguez A; Berciano J; Banzo I; Infante J
Neurology; 2017 Aug; 89(5):439-444. PubMed ID: 28679601
[TBL] [Abstract][Full Text] [Related]
3. A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.
Bregman N; Thaler A; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N;
Brain Struct Funct; 2017 Apr; 222(3):1207-1218. PubMed ID: 27401793
[TBL] [Abstract][Full Text] [Related]
4. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
5. Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation.
Thaler A; Gonen T; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Bloem BR; Giladi N; Hendler T;
Brain Imaging Behav; 2019 Aug; 13(4):1009-1020. PubMed ID: 29971685
[TBL] [Abstract][Full Text] [Related]
6. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
[TBL] [Abstract][Full Text] [Related]
7. Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers.
Jacob Y; Rosenberg-Katz K; Gurevich T; Helmich RC; Bloem BR; Orr-Urtreger A; Giladi N; Mirelman A; Hendler T; Thaler A
Hum Brain Mapp; 2019 Jun; 40(8):2546-2555. PubMed ID: 30793410
[TBL] [Abstract][Full Text] [Related]
8. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.
Vilas D; Ispierto L; Álvarez R; Pont-Sunyer C; Martí MJ; Valldeoriola F; Compta Y; de Fabregues O; Hernández-Vara J; Puente V; Calopa M; Jaumà S; Campdelacreu J; Aguilar M; Quílez P; Casquero P; Lomeña F; Ríos J; Tolosa E
Parkinsonism Relat Disord; 2015 Oct; 21(10):1170-6. PubMed ID: 26306001
[TBL] [Abstract][Full Text] [Related]
9. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
Pont-Sunyer C; Tolosa E; Caspell-Garcia C; Coffey C; Alcalay RN; Chan P; Duda JE; Facheris M; Fernández-Santiago R; Marek K; Lomeña F; Marras C; Mondragon E; Saunders-Pullman R; Waro B;
Mov Disord; 2017 May; 32(5):726-738. PubMed ID: 28370517
[TBL] [Abstract][Full Text] [Related]
10. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
[TBL] [Abstract][Full Text] [Related]
11. Serial DaT-SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years' follow-up.
Sánchez-Rodríguez A; Martínez-Rodríguez I; Sánchez-Juan P; Sierra M; González-Aramburu I; Rivera-Sánchez M; Andrés-Pacheco J; Gutierrez-González Á; García-Hernández A; Madera J; Delgado-Alvarado M; Infante J
Eur J Neurol; 2021 Dec; 28(12):4204-4208. PubMed ID: 34407293
[TBL] [Abstract][Full Text] [Related]
12. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
[TBL] [Abstract][Full Text] [Related]
13. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
[TBL] [Abstract][Full Text] [Related]
14. Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.
Pont-Sunyer C; Iranzo A; Gaig C; Fernández-Arcos A; Vilas D; Valldeoriola F; Compta Y; Fernández-Santiago R; Fernández M; Bayés A; Calopa M; Casquero P; de Fàbregues O; Jaumà S; Puente V; Salamero M; José Martí M; Santamaría J; Tolosa E
PLoS One; 2015; 10(7):e0132368. PubMed ID: 26177462
[TBL] [Abstract][Full Text] [Related]
15. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
16. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
18. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
Thaler A; Mirelman A; Helmich RC; van Nuenen BF; Rosenberg-Katz K; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T;
Cortex; 2013 Oct; 49(9):2501-11. PubMed ID: 23357204
[TBL] [Abstract][Full Text] [Related]
19. Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.
Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Shenhar-Tsarfaty S; Mirelman A
J Neurol; 2021 Apr; 268(4):1517-1525. PubMed ID: 33388928
[TBL] [Abstract][Full Text] [Related]
20. Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study.
Vilas D; Segura B; Baggio HC; Pont-Sunyer C; Compta Y; Valldeoriola F; José Martí M; Quintana M; Bayés A; Hernández-Vara J; Calopa M; Aguilar M; Junqué C; Tolosa E;
Mov Disord; 2016 Dec; 31(12):1820-1828. PubMed ID: 27653520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
